ULIPRISTALUM ACETATUM - search results

Ireland - English - HPRA (Health Products Regulatory Authority)

pepcid duo chewable tablets famotidine 10mg magnesium hydroxide 165mg calcium carbonate 800mg

johnson & johnson (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - 10/165/800 milligram(s) - h2-receptor antagonists; famotidine, combinations

Ireland - English - HPRA (Health Products Regulatory Authority)

utrogestan 100 mg capsules, soft

laboratoires besins international - progesterone - capsule, soft - 100 milligram(s) - progesterone

Ireland - English - HPRA (Health Products Regulatory Authority)

sporanox 100mg capsules

janssen sciences ireland uc - itraconazole - capsule, hard - 100 milligram(s) - triazole derivatives; itraconazole

Ireland - English - HPRA (Health Products Regulatory Authority)

pepcid duo chewable tablets famotidine 10mg magnesium hydroxide 165mg calcium carbonate 800mg

jntl consumer health i (ireland) limited - famotidine; magnesium hydroxide; calcium carbonate - chewable tablet - h2-receptor antagonists; famotidine, combinations

Australia - English - Department of Health (Therapeutic Goods Administration)

itracap itraconazole 100 mg capsule blister pack

arrotex pharmaceuticals pty ltd - itraconazole, quantity: 100 mg - capsule - excipient ingredients: hypromellose; macrogol 20000; sucrose; hydrolysed maize starch; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - itracap is indicated for use in adults for the treatment of: ? superficial dermatomycoses not responding to topical treatment. ? fungal keratitis which has failed to respond to topical treatment or where the disease is either progressing rapidly or is immediately sight threatening. ? pityriasis versicolor not responding to any other treatment. ? vulvovaginal candidiasis not responding to topical treatment. ? oral candidiasis in immunocompromised patients. ? onychomycosis caused by dermatophytes. ? systemic mycoses: - systemic aspergillosis, histoplasmosis, sporotrichosis. - treatment and maintenance therapy in aids patients with disseminated or chronic pulmonary histoplasmosis infection. - treatment of oropharyngeal and/or oesophageal candidiasis when first line systemic antifungal therapy is inappropriate or has proven ineffective. - treatment of non-invasive candidiasis in non-neutropenic patients when first-line systemic antifungal therapy is inappropriate or has proven ineffective. this may be due to underlying pathology, insensitivity of the pathogen or drug toxicity.